American Well Corp (AMWL) Stock Price Today
Aura AI Summary
Key Stats
- $220.09MMarket Cap
- -Volume
- HealthSector
- $13.5852W High
- $3.7852W Low
- -Typical Hold Time
- $27.13MEnterprise Value
- -Div Yield
- -Trading Activity
Track American Well Corp (AMWL) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, American Well Corp has traded between a low of $3.78 and a high of $13.58, highlighting its annual price range. Buy and sell American Well Corp shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Most Recent News
Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured
Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...
Life360 director Morin Brit sells 15,582 shares for $1 million
Morin Brit, a director at Life360, sold 15,582 shares of the company, generating $1 million from the transaction. This sale may indicate a personal financial decision or portfolio adjustment by the director. Investors might watch for any further insi...
AbCellera's stock jumps after successful menopause drug trial and CFO insider buying.
AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.